SGLT 2 inhibitors in Type 1 diabetes

Elisabeth Buur Stougaard; Hanan Amadid; Esben Søndergaard; Marit Eika Jørgensen; Frederik Persson; Peter Rossing

SGLT 2 inhibitors in Type 1 diabetes

Elisabeth Buur Stougaard, Hanan Amadid, Esben Søndergaard, Marit Eika Jørgensen, Frederik Persson, Peter Rossing

Steno Diabetes Center Copenhagen

Abstract

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9% to 4,0% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.

Original language	English
Journal	Ugeskrift for Laeger
Volume	182
Issue number	35
ISSN	0041-5782
Publication status	Published - 24 Aug 2020

Cite this

@article{67610c37c2b241089967d0c28a602a9c,

title = "SGLT 2 inhibitors in Type 1 diabetes",

abstract = "The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9\% to 4,0\% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.",

author = "Stougaard, \{Elisabeth Buur\} and Hanan Amadid and Esben S{\o}ndergaard and J{\o}rgensen, \{Marit Eika\} and Frederik Persson and Peter Rossing",

year = "2020",

month = aug,

day = "24",

language = "English",

volume = "182",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "35",

}

TY - JOUR

T1 - SGLT 2 inhibitors in Type 1 diabetes

AU - Stougaard, Elisabeth Buur

AU - Amadid, Hanan

AU - Søndergaard, Esben

AU - Jørgensen, Marit Eika

AU - Persson, Frederik

AU - Rossing, Peter

PY - 2020/8/24

Y1 - 2020/8/24

N2 - The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9% to 4,0% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.

AB - The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9% to 4,0% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.

UR - https://www.scopus.com/pages/publications/85089794146

M3 - Journal article

C2 - 32829747

AN - SCOPUS:85089794146

SN - 0041-5782

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 35

ER -

SGLT 2 inhibitors in Type 1 diabetes

Abstract

Other files and links

Fingerprint

Cite this